Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $11,488.35 in Stock

Posted by Stanley Muller on May 19th, 2026

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) insider David Malcom Rodman sold 417 shares of the firm’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $27.55, for a total transaction of $11,488.35. Following the completion of the sale, the insider owned 63,443 shares of the company’s stock, valued at $1,747,854.65. This trade represents a 0.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

On Tuesday, May 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $29.36, for a total transaction of $186,377.28.
On Wednesday, May 13th, David Malcom Rodman sold 14,056 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $28.58, for a total transaction of $401,720.48.
On Monday, May 11th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $29.71, for a total transaction of $64,500.41.
On Friday, April 17th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $31.33, for a total transaction of $13,033.28.
On Wednesday, April 15th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.66, for a total transaction of $175,585.68.
On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.54, for a total transaction of $373,099.32.
On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.38, for a total transaction of $59,414.60.
On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.37, for a total transaction of $173,744.76.
On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.26, for a total transaction of $369,163.08.
On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.84, for a total transaction of $58,269.64.

Mineralys Therapeutics Stock Down 1.4%

MLYS stock traded down $0.36 during trading on Tuesday, hitting $26.03. The company had a trading volume of 703,157 shares, compared to its average volume of 997,992. The firm has a market capitalization of $2.15 billion, a P/E ratio of -12.70 and a beta of 0.49. Mineralys Therapeutics, Inc. has a 52-week low of $12.59 and a 52-week high of $47.65. The company has a 50 day simple moving average of $27.05 and a 200-day simple moving average of $32.37.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.04. Sell-side analysts forecast that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on MLYS shares. Bank of America raised their price target on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. TD Cowen started coverage on shares of Mineralys Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Tuesday, April 21st. Jefferies Financial Group reaffirmed a “hold” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a research note on Friday, March 13th. Finally, Wall Street Zen downgraded shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Mineralys Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

Get Our Latest Stock Report on Mineralys Therapeutics

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MLYS. State Street Corp increased its position in Mineralys Therapeutics by 144.4% during the 4th quarter. State Street Corp now owns 3,184,999 shares of the company’s stock valued at $115,584,000 after purchasing an additional 1,881,976 shares during the period. Farallon Capital Management LLC purchased a new position in Mineralys Therapeutics during the 3rd quarter valued at about $63,442,000. Price T Rowe Associates Inc. MD increased its position in Mineralys Therapeutics by 6,097.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,325,120 shares of the company’s stock valued at $48,089,000 after purchasing an additional 1,303,737 shares during the period. Holocene Advisors LP purchased a new position in Mineralys Therapeutics during the 3rd quarter valued at about $45,708,000. Finally, Janus Henderson Group PLC increased its position in Mineralys Therapeutics by 6,012.8% during the 4th quarter. Janus Henderson Group PLC now owns 1,213,265 shares of the company’s stock valued at $44,005,000 after purchasing an additional 1,193,417 shares during the period. Hedge funds and other institutional investors own 84.46% of the company’s stock.

About Mineralys Therapeutics

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.